Press Releases April 7, 2026 08:00 PM

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Aclaris Therapeutics to Present at H.C. Wainwright Inflammatory Skin Disease Conference

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
ACRS

Aclaris Therapeutics, a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, announced participation of its CEO and senior leadership in a fireside chat at the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026. The event will be webcast live and archived on the company's website.

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
ACRS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aclaris Therapeutics is focused on developing novel treatments for immuno-inflammatory diseases with unmet medical needs.
  • The CEO and senior leadership will discuss company developments and outlook during the virtual conference fireside chat.
  • The conference participation provides an opportunity for the company to communicate directly with investors and stakeholders in the healthcare and biotech sectors.

WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]


Risks

  • As a clinical-stage biopharmaceutical firm, Aclaris faces risks related to clinical trial outcomes and regulatory approvals, impacting biotechnology and pharmaceutical markets.
  • Market reception to the company's updates and progress may be uncertain, potentially influencing investor sentiment in the healthcare sector.
  • Dependence on successful R&D and product development timelines presents operational risks inherent to the biopharmaceutical industry.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026